Elsevier

The Journal of Pediatrics

Volume 123, Issue 5, November 1993, Pages 791-794
The Journal of Pediatrics

Clinical and laboratory observation
Response to Haemophilus influenzae type bconjugate vaccine in chronically ill premature infants1

https://doi.org/10.1016/S0022-3476(05)80862-5Get rights and content

Twenty-two premature infants with chronic lung disease (median gestational age 28 weeks) received polyribosylribitol phosphate-outer membrane protein conjugate Haemophilus vaccine at 2 and 4 months of chronologic age. The proportions with antibodies to polyribosylribitol phosphate at levels >1 μg/ml after doses 1 and 2 were 27% and 55%; geometric mean titers were 0.43 and 0.73 μg/ml, significantly lower than values for term infants.

References (12)

There are more references available in the full text version of this article.

Cited by (43)

  • Immunology of the Fetus and Newborn

    2018, Avery's Diseases of the Newborn: Tenth Edition
  • Plasma cell and serum antibody responses to influenza vaccine in preterm and full-term infants

    2017, Vaccine
    Citation Excerpt :

    PT infants are born with immature immune systems, including defects in B-cell function, yet it is unclear how prematurity affects the quality of the cellular vaccine responses or when immune function matures after birth [2]. Compared to full term (FT) infants, extremely PT infants have decrements in serum titers to a number of vaccines that can persist at least to school age [3–18]. Although PT and FT infants exhibit similar acute serological responses to influenza vaccines [19], no studies have assessed long term immunogenicity or cellular immunity following influenza vaccine among PT infants.

  • Haemophilus influenzae vaccines

    2012, Vaccines: Sixth Edition
View all citing articles on Scopus
1

Supported by Merck Sharp & Dohme.

View full text